Topics

Latest "Pharmaceutical Executive Conferences website" News Stories - Page: 3

16:42 EDT 15th September 2019 | BioPortfolio

Here are the most relevant search results for "Pharmaceutical Executive Conferences website" found in our extensive news archives from over 250 global news sources.

More Information about Pharmaceutical Executive Conferences website on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Pharmaceutical Executive Conferences website for you to read. Along with our medical data and news we also list Pharmaceutical Executive Conferences website Clinical Trials, which are updated daily. BioPortfolio also has a large database of Pharmaceutical Executive Conferences website Companies for you to search.

Showing "Pharmaceutical Executive Conferences website" News Articles 51–75 of 16,000+

Friday 13th September 2019

Oncology Venture - New CEO as company moves toward late stage

Oncology Venture announced on 4 September 2019 that it has appointed a new CEO, Steve Carchedi, former senior executive of J&J and Mallinckrodt. This comes at a critical juncture for the company as...


Aytu BioScience to acquire Innovus Pharmaceuticals

This initial consideration to Innovus common shareholders is estimated to consist of approximately 4.2 million shares of Aytu stock. Additional consideration for up to $16 million in milestone The post Aytu BioScience to acquire Innovus Pharmaceuticals appeared first on Pharmaceutical Business review.

UKRI Chief Executive Sir Mark Walport to step down in 2020

Sir Mark Walport, Chief Executive of UK Research and Innovation (UKRI), the national funding agency responsible for science and research investment in the UK, has announced he is to retire for the role next year. The decision to leave the organisation in 2020 will mark the end of a three-year tenure at its helm, beginning in 2017 when Walport was appointed to “create a single, ambitious organisa...


FDA approves GSK’s Nucala for young children with severe eosinophilic asthma

Nucala is claimed to be the only targeted biologic to secure approval for the condition in the six to 11-year age group in the US. The FDA approval The post FDA approves GSK’s Nucala for young children with severe eosinophilic asthma appeared first on Pharmaceutical Business review.

Turbo-charging pharmaceutical biotechnology simulations

Demand for biopharmaceuticals is strong: biopharmaceutical active ingredients – in other words, genetically engineered drugs – accounted for seven of the ten top-selling medications in the world in 2018. And the proportion is set to rise, as biopharmaceuticals can be used to combat conditions such a...

AIM ImmunoTech Inc. to Present at the Fall Investor Summit on September 16th-17th in New York City

OCALA, FL / ACCESSWIRE / September 13, 2019 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases - such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) - will be presenting at this year's Fall Investor Summit on September 16th-17th in New York City...

Thursday 12th September 2019

Adamas Pharmaceuticals Appoints Neil McFarlane as Chief Executive Officer

- Gregory Went, Ph.D., Founder, transitions to a strategic advisory role - David Mahoney, lead independent director, appointed to Chairman of the Board EMERYVILLE, Calif., Sept. 13, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced t...

Traditional Chinese Medicine Giant DEEJ Partners with 111 for Direct Sourcing

SHANGHAI, Sept. 12, 2019 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading integrated online and offline healthcare platform, today announced the signing of a strategic cooperation agreement with Dong-E-E-Jiao Co., Ltd. ("DEEJ") (SZ: 000423), a leading company principally engaged in the research, development, production and sale of traditional...

FDA approves Nucala to treat severe eosinophilic asthma in children

GlaxoSmithKline (GSK) has received the approval of the US Food and Drug Administration (FDA) for its Nucala (mepolizumab) drug to...Read More... The post FDA approves Nucala to treat severe eosinophilic asthma in children appeared first on Pharmaceutical Technology.

Inotrem secures funds to develop septic shock treatment

Biotechnology company Inotrem has secured series B funding to develop immunotherapy candidates targeting septic shock and chronic inflammatory conditions. The...Read More... The post Inotrem secures funds to develop septic shock treatment appeared first on Pharmaceutical Technology.

Penn researchers study cancer therapy in heart disease treatment

A research team from Penn Medicine at the University of Pennsylvania has been studying CAR T-cell therapy, which is used...Read More... The post Penn researchers study cancer therapy in heart disease treatment appeared first on Pharmaceutical Technology.

SamaraCare and Samaritan Counseling Center: Now stronger together.

On July 1, 2019, SamaraCare Counseling and Samaritan Counseling Center, joined forces to become one of Chicagoland's largest providers of high-quality mental health services. NAPERVILLE and WINNETKA, Ill. (PRWEB) September 12, 2019 On July 1, 2019, SamaraCare Counseling and Samaritan Counseling Center, joined forces to become one of Chicagoland's largest providers of high-quality mental h...

Menarini: Elcin Barker Ergun Group CEO

FLORENCE, Italy, Sept. 12, 2019 /PRNewswire/ -- The Board of Directors has appointed Mrs. Elcin Barker Ergun as CEO of Menarini Group. "Elcin Barker Ergun is the ideal addition to the Menarini team, in order to continue the agenda of growth in geography and therapeutic areas," commented Eric Cornut, Chairman of Menarini.

Personalis Appoints Karin Eastham to Its Board of Directors

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that it has appointed Karin Eastham as an independent director to its Board of Directors. Ms. Eastham brings more than 36 years of experience as both an executive and as an independent director in the biotechnology industry, with deep expertise in finance and operations. From May 2004 until her retirement i...

Cutera Receives Additional Approval from Health Canada for its truSculpt® iD Body Sculpting Technology

CUTERA®, INC., (Nasdaq: CUTR) ("Cutera" or the "Company") a leading provider of laser, light and other energy-based aesthetic systems for practitioners worldwide, announced today that Health Canada recently granted regulatory approval expanding the indications for use for truSculpt® iD to include reduction of circumference of the abdomen and non-invasive lipolysis (the permanent removal of fat ...

Domino’s Pizza of Canada® Once Again Partners with SickKids

Every time a Customer Orders the “SickKids Special Offer,” $2 will be donated to SickKids! On Sunday, September 15, Domino’s Pizza stores in the Greater Toronto Area will be raising “dough” for SickKids Foundation. During this one-day event, customers can receive a “Medium, cheese or pepperoni pizza for $5.00 (carry-out only).” $2.00 from each of these pizzas sold will be donated...

National Health Care Expert Darin Selnick Joins Sync.MD as Advisor

Today, Sync.MD announced that nationally recognized health expert Darin Selnick has joined as advisor to the health care technology startup. Sync.MD allows patients to take back control of their health care information by offering an innovative online platform to safely and securely manage access to medical records right from their smartphone. Selnick has held a variety of senior positions in t...

Devoted Health and Publix Team Up to Improve Flu Vaccination Coverage in Florida

Devoted Health (www.devoted.com), a next generation Medicare Advantage plan, announced today a partnership with Publix Pharmacy (www.publix.com) to provide flu shots at a series of health f

Dr. Dan Holtzclaw Celebrates 11 Years as Editor-in-Chief for the Journal of Implant & Advanced Clinical Dentistry

Dr. Holtzclaw celebrates his 11th year as Editor-in-Chief of the highly respected Journal of Implant & Advanced Clinical Dentistry. This esteemed publication discusses some of the most complex dental implant cases, including those placed in patients with severe bone loss. AUSTIN, Texas (PRWEB) September 12, 2019 Dr. Dan Holtzclaw, founder of DIA Dental Implant Center in San Antonio and Austin...

KRS Global Biotechnology, Inc. Issues Voluntary Nationwide Recall of All Human and Animal Sterile Drug Products Due to Lack of Assurance of Sterility

KRS Global Biotechnology, Inc. is voluntarily recalling all lots of unexpired human and animal drugs intended to be sterile to the consumer level. The products are being recalled due to lack of assurance of sterility. Administration of a drug product intended to be sterile that is not sterile could result in serious infections which may be life-threatening. To date, KRS Global Biotechnology, In...

Stage IV NSCLC and New Targets: RET

Post ASCO 2019 Lung Cancer Round Table Discussion - Stage IV NSCLC and New Targets: RETH. Jack West, MD, Founder, President and CEO

NeuroVive Pharmaceutical (NVP) - Steady progress with core assets

Edison Investment Research - Pharmaceuticals & healthcare - NeuroVive Pharmaceutical: NeuroVive’s core R&D assets in genetic mitochondrial diseases have made steady progress over the past several months. Notable newsflow includes KL1333 proceeding to the second part of its study and NeuroSTAT receiving the FDA’s fast track designation. Potential near-term milestones include initial...

Pharma consultancy Boyds enhances clinical, medical affairs services

The pharmaceutical and biotech product development consultancy Boyds acquires Blue Duck Consulting to boost its clinical and medical affairs services offering.

Scotland reaches access agreement with Vertex for CF drug Orkambi

Vertex Pharmaceuticals has announced two of its cystic fibrosis (CF) drugs, Orkambi (lumacaftor-ivacaftor) and Symkevi (tezacaftor/ivacaftor) will now be available...Read More... The post Scotland reaches access agreement with Vertex for CF drug Orkambi appeared first on Pharmaceutical Technology.

PharmaCyte Biotech Releases Results of Shareholder Meeting and Provides Information on Upcoming Shareholder Update Call

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature


Quick Search

News Quicklinks